HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Their initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Biotechnology

Hillevax

Hillevax's headquarters in Boston, MA, United States

Rob Hershberg

John Markels

Chao Huang

Lynn Ferrucci

Anju Chatterji

Shane Maltbie

Astrid Borkowski

Paul Bavier

Aditya Kohli

Gary Dubin

Nanette Cocero

Description

People (5)

Shane Maltbie

Ivana Dinkova, CPA, MBA

Sonja Moua

Sam Walker

Chao Huang

Jobs